柏柏林通过抑制cGAS-STING通路和缓解铁灭菌来缓解肌病
Yeshuai Shen1, Wenting Wei2, Yang Lu3
1The Second Affiliated Hospital of Soochow University, China; The Affiliated Hospital of Xuzhou Medical University, China.
概括
柏柏林有效地通过减少细胞损伤和氧化应激来治疗肌病. 这种天然化合物通过cGAS-STING通路缓解铁亡,一种细胞死亡,为肌病提供了潜在的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 来自Coptis根茎的柏柏林显示出治疗前景.
- 肌病是一种使人衰弱的疾病,治疗选择有限.
研究的目的:
- 为了研究柏柏林在治疗肌病的疗效.
- 阐明贝贝林治疗效果背后的分子机制.
主要方法:
- 在老鼠中的I型原酶诱导肌病模型.
- 细胞测试以评估分子通路.
- 测量氧化应激标志物 (MDA,ROS) 和抗氧化剂水平 (GSH,GPX4).
- 抑制和诱导cGAS-STING通路和铁亡.
主要成果:
- 在大鼠模型中,柏柏林治疗改善了肌病变.
- 柏柏林降低了cGAS-STING通路的激活,减少了马隆迪化物 (MDA) 和活性氧物种 (ROS) 的积累.
- 柏柏林增加了谷氨 (GSH) 和谷氨过氧化酶4 (GPX4) 的表达,表明铁亡的缓解.
- 伊米达基因埃拉斯 (IKE) 逆转了柏柏林的治疗效果,证实了铁亡的参与.
结论:
- 柏柏林通过抑制铁亡来缓解肌病.
- cGAS-STING通路是柏柏林治疗作用的关键调解者.
- 柏柏林为治疗肌病症提供了一个有前途的治疗药物.
相关概念视频
Drugs that Stabilize Microtubules
1.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
564
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
564
Myasthenia Gravis: Overview and Treatment
980
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
980
Enzyme Inhibition
77.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.5K


